Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases
Lisa KobrynskiDepartment of Pediatrics, Emory University, Atlanta, GA, USAAbstract: Since the 1950s, replacement of immunoglobulin G using human immunoglobulin has been the standard treatment for primary immunodeficiency diseases with defects in antibody production. These patients suffer from recurr...
Guardado en:
Autor principal: | Kobrynski L |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2012
|
Materias: | |
Acceso en línea: | https://doaj.org/article/5352b791509b4c489e7611f4de1324f9 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
CLINICAL AND EPIDEMIOLOGICAL ASPECTS OF PRIMARY IMMUNODEFICIENCY DISEASES (PID) AND EARLY DIAGNOSIS OPTIONS
por: I. A. Korsunskiy, et al.
Publicado: (2017) -
Immunoglobulin G4-related kidney disease: Pathogenesis, diagnosis, and treatment
por: Ke Zheng, et al.
Publicado: (2017) -
Long-term treatment with subcutaneous immunoglobulin in multifocal motor neuropathy
por: Luca Gentile, et al.
Publicado: (2021) -
Subcutaneous immunoglobulin replacement for treatment of humoral immune dysfunction in patients with chronic lymphocytic leukemia.
por: S Shahzad Mustafa, et al.
Publicado: (2021) -
A critical evaluation of the role of subcutaneous abatacept in the treatment of rheumatoid arthritis: patient considerations
por: Wells AF, et al.
Publicado: (2014)